Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
771.120.17%
QQQ
716.510.11%
BTC/USD
64547.000.0796%
DIA
543.750.17%
GLD
392.420.71%
TLT
83.050.06%

Atossa Therapeutics Inc

ATOSNASDAQ
Trade with Public
Trade with Public
$2.39
0.083.46%
At close: Aug 5, 5:00 PM EST
$2.35
-0.04-1.67%
After Hours: 4:25 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Atossa Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Atossa Therapeutics (ATOS).

Price Target Range — 12 Quarters

Analyst Consensus — 5 Analysts

5Buy
Consensus RatingBuy# Analysts5Avg. Consensus PT$16Upside to Avg. PT+591.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 7, 2026Rodman & RenshawMichael G. King Jr.InitiateBuy$12
Apr 10, 2026Ascendiant CapitalEdward WooPT CutBuy$120→$24
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and lowers the price target from $120 to $24.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7 to $25.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7.75 to $8.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.75

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7.5 to $7.75.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.5

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7.25 to $7.5.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved